A large international study led by researchers at the University of Oxford and the University of Virginia (USA) has identified a new model for predicting outcomes for hypertrophic cardiomyopathy (HCM) \u2013 a heart condition that is the most frequent cause of sudden cardiac death in younger individuals.
Researchers from the Department of Oncology in collaboration with the Department of Chemistry have developed a promising new compound designed to reduce tumour hypoxia, a major cause of radiotherapy resistance.
Two students from the University of Oxford\u2019s MSc in Global Healthcare Leadership programme, jointly delivered by the Nuffield Department of Primary Care Health Sciences (NDPCHS) and Sa\u00efd Business School, have co-founded a new social enterprise called \u2018Synergya\u2019, designed to help health and sustainability ventures scale through structured collaboration.
On World Ovarian Cancer Day, we recognise the impact ovarian cancer has on women and families worldwide, and the urgent need for earlier diagnosis, improved treatment, and better survival outcomes. The day also highlights the importance of continued research to improve understanding of ovarian cancer biology, diagnosis, treatment, and patient outcomes.
A new study published in Nature Medicine suggests that simple, low-cost tools could help health workers identify children at risk of life-threatening infection earlier, improving access to urgent care in across South and South East Asia.
A major new NIHR funded programme grant aims to make medical implants safer and better value for money in the NHS. The project will develop a robust framework to assess the long-term risks, benefits and costs of implants.
A team from the University of Oxford and Oxford Health NHS Foundation Trust created a therapeutic horticulture garden in a psychiatric intensive care unit for young people, as part of a new study looking at how green spaces can benefit patients and staff.
A Phase II Study, published in The Lancet Obstetrics, Gynaecology & Women's Health, highlights the potential of a new molecular imaging agent, \u201899mTc-maraciclatide\u2019, when used alongside a non-invasive scan to diagnose and monitor the development and treatment of Endometriosis.
A new clinical trial led by researchers at the Jenner Institute in collaboration Ifakara Health Institute Tanzania, suggests that a single-dose rabies vaccine could provide safe, long-lasting protection in both adults and children. The research could lead to a simpler, lower-cost approach that could transform rabies prevention in high-risk regions.
A new study by Tommy\u2019s researchers, led by Professor Arri Coomarasamy, from the Nuffield Department of Women\u2019s & Reproductive Health, suggests that offering follow-up care from the first miscarriage could help prevent around 10,000 pregnancy losses each year in the UK.
Researchers from the University of Oxford's Radcliffe Department of Medicine and the University of Surrey have discovered that a key immune enzyme controls inflammation in a way that does not depend on its well-known function.
A new study led by researchers at the University of Oxford demonstrates that the huge success of effective antiretroviral therapy (ART) against HIV could have altered the course of human evolution.
Professor Samira Lakhal-Littleton from the Department of Physiology, Anatomy and Genetics is part of a team of international collaborators awarded 15 million euros, including 2.6 million euros to Oxford, from the European Research Council.
Researchers from the Department of Oncology are part of a \u20ac50 million European project looking at how innovative medical and digital technologies can improve the early detection of heart-related problems in cancer patients and survivors.
New data published today in the European Society for Medical Oncology (ESMO) Real World Data and Digital Oncology show that more than half of people receiving systemic anticancer treatment had a history of obesity, compared with only around one in four who were classified as obese at the time their treatment began.
The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world\u2019s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.
![\"Graphics](\"https://www.medsci.ox.ac.uk/news/heart-scan-and-blood-test-improve-risk-prediction-for-inherited-heart-condition-major-study-finds/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n